Evidence map›Paper›PMID 38513254›Full record

ArticleMedical physics2024

Superparamagnetic iron oxide nanoparticle enhanced percutaneous microwave ablation: Ex-vivo characterization using magnetic resonance thermometry.

Sharath K Bhagavatula, Sajanlal R Panikkanvalappil, Junichi Tokuda, Vincent Levesque, Zuzana Tatarova, Guigen Liu, John E Markert, Oliver Jonas

Abstract read
In one paragraph

Article in Medical physics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sharath K BhagavatulaDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Sajanlal R PanikkanvalappilDepartment of Imaging, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
Junichi TokudaDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Vincent LevesqueDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Zuzana TatarovaDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Guigen LiuDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
John E MarkertDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Oliver JonasDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Funding

TRD 3 - Enabling Technologies for Intraprocedural GuidanceP41EB028741 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARE M TEMPANY · 2021 to 2026
$10.7M
Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patientsR01CA232174 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HATA, NOBUHIKO, JONAS, OLIVER · 2019 to 2023
$3.4M
Implantable microdevices with integrated optical imaging for high-throughput in situ tumor response and drug sensitivity measurementR37CA224144 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI JONAS, OLIVER · 2018 to 2023
$2.4M
Four-dimensional multi-modality microimaging-microdevice system for high throughput drug screening in vivoK25EB032900 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI LIU, GUIGEN · 2022 to 2025
$694k
NCI NIH HHS R01 CA232174NCI NIH HHS R37 CA224144NIBIB NIH HHS K25 EB032900NIBIB NIH HHS P41 EB028741NIH HHS K25EB032900NIH HHS P41EB028741NIH HHS R37CA224144
6 · The paper itself

Abstract

backgroundPercutaneous microwave ablation (pMWA) is a minimally invasive procedure that uses a microwave antenna placed at the tip of a needle to induce lethal tissue heating. It can treat cancer and other diseases with lower morbidity than conventional surgery, but one major limitation is the lack of control over the heating region around the ablation needle. Superparamagnetic iron oxide nanoparticles have the potential to enhance and control pMWA heating due to their ability to absorb microwave energy and their ease of local delivery. PURPOSE: The purpose of this study is to experimentally quantify the capabilities of FDA-approved superparamagnetic iron oxide Feraheme nanoparticles (FHNPs) to enhance and control pMWA heating. This study aims to determine the effectiveness of locally injected FHNPs in increasing the maximum temperature during pMWA and to investigate the ability of FHNPs to create a controlled ablation zone around the pMWA needle.

methodsPMWA was performed using a clinical ablation system at 915 MHz in ex-vivo porcine liver tissues. Prior to ablation, 50 uL 5 mg/mL FHNP injections were made on one side of the pMWA needle via a 23-gauge needle. Local temperatures at the FHNP injection site were directly compared to equidistant control sites without FHNP. First, temperatures were compared using directly inserted thermocouples. Next, temperatures were measured non-invasively using magnetic resonance thermometry (MRT), which enabled comprehensive four-dimensional (volumetric and temporal) assessment of heating effects relative to nanoparticle distribution, which was quantified using dual-echo ultrashort echo time (UTE) subtraction MR imaging. Maximum heating within FHNP-exposed tissues versus control tissues were compared at multiple pMWA energy delivery settings. The ability to generate a controlled asymmetric ablation zone using multiple FHNP injections was also tested. Finally, intra-procedural MRT-derived heat maps were correlated with gold standard gross pathology using Dice similarity analysis.

resultsMaximum temperatures at the FHNP injection site were significantly higher than control (without FHNP) sites when measured using direct thermocouples (93.1 ± 6.0°C vs. 57.2 ± 8.1°C, p = 0.002) and using non-invasive MRT (115.6 ± 13.4°C vs. 49.0 ± 10.6°C, p = 0.02). Temperature difference between FHNP-exposed and control sites correlated with total energy deposition: 66.6 ± 17.6°C, 58.1 ± 8.5°C, and 20.8 ± 9.2°C at high (17.5 ± 2.2 kJ), medium (13.6 ± 1.8 kJ), and low (8.8 ± 1.1 kJ) energies, respectively (all pairwise p < 0.05). Each FHNP injection resulted in a nanoparticle distribution within 0.9 ± 0.2 cm radially of the injection site and a local lethal heating zone confined to within 1.1 ± 0.4 cm radially of the injection epicenter. Multiple injections enabled a controllable, asymmetric ablation zone to be generated around the ablation needle, with maximal ablation radius on the FHNP injection side of 1.6 ± 0.2 cm compared to 0.7 ± 0.2 cm on the non-FHNP side (p = 0.02). MRT intra-procedural predicted ablation zone correlated strongly with post procedure gold-standard gross pathology assessment (Dice similarity 0.9).

conclusionsLocally injected FHNPs significantly enhanced pMWA heating in liver tissues, and were able to control the ablation zone shape around a pMWA needle. MRI and MRT allowed volumetric real-time visualization of both FHNP distribution and FHNP-enhanced pMWA heating that was useful for intra-procedural monitoring. This work strongly supports further development of a FHNP-enhanced pMWA paradigm; as all individual components of this approach are approved for patient use, there is low barrier for clinical translation.

Indexed as

Ablation TechniquesMagnetic Iron Oxide NanoparticlesMicrowavesThermometryAnimalsLiverMagnetic Resonance ImagingSwineTemperatureinterventional radiologymagnetic resonance thermometrymicrowave ablationminimally invasive treatmentsuperparamagnetic iron oxide nanoparticles

Identifiers

PMID38513254
PMCPMC11406496

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.